8-K - ArriVent BioPharma, Inc. Common Stock | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

ArriVent BioPharma, Inc. announced financial results for the full year ended December 31, 2025, reporting net loss of $166.3 million and cash and investments of $312.8 million expected to fund operations into 3Q 2027. The company highlighted progress on firmonertinib Phase 3 trials and ADC pipeline advancements.

Key Takeaways

1Cash and investments of $312.8 million as of December 31, 2025, expected to fund operations into 3Q 2027

2Net loss of $166.3 million for year ended December 31, 2025 vs $80.5 million in 2024

3Research and development expenses $153.4 million for 2025 vs $79.0 million in 2024

4Topline Phase 3 data for firmonertinib in EGFR exon 20 insertion mutant NSCLC expected mid-2026

5First patient dosed in Phase 3 ALPACCA study for EGFR PACC mutant NSCLC in December 2025

6ARR-217 Phase 1 trial ongoing with first patient dosed in March 2026

Current Report Details

Event Type

Financial Results

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

and in the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amen

Financial Results

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated March 5, 2026. 104 Cover Page Interactive Data File (embedde

Exhibits Only

Results of Operations

Full Year 2025

Metric	Value	Basis	Prior Period
Research and development expenses	$153.4K	GAAP	$79.0K
General and administrative expenses	$24.2K	GAAP	$15.3K
Net loss	$166.3K	GAAP	$80.5K

Exhibits (2)

8-K

99.1

EX-99.1